Sign up to save your podcasts
Or
Share Experts Talk CLL #7 : First-Line CLL New Treatment Options in Canada
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Experts Talk CLL #7 : First-Line CLL New Treatment Options in Canada
A discussion between Dr. Peter Anglin and Dr. Versha Banerji (June 2022)
Dr. Anglin and Dr. Banerji revisit the management of treatment naïve CLL in Canada. Dr. Banerji describes her approaches with novel agents focusing on initial screening for associated risk factors as well as prevention and management of common treatment-related adverse events. She covers concerns related to cardiovascular risks with BTKi, infusion reactions with obinutuzumab and tumour lysis syndrome with venetoclax.
Peter Anglin, MD, FRCPC, MBA, Hematologist/Oncologist, Physician Lead, Stronach Regional Cancer, Centre Newmarket, ON
Versha Banerji, MD, FRCPC, Clinician Scientist and Associate Professor, Faculty of Medicine, Departments of Internal Medicine, Biochemistry & Medical Genetics, Max Rady School of Medicine, Rady Faculty of Health Sciences, University of Manitoba, CLL clinic and research Co-Lead Hematologist, CancerCare Manitoba, Senior Scientist, CancerCare Manitoba Research Institute, Adjunct Professor, Department of Biology, University of Winnipeg
This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.
View all episodes
By Various Topics on AML and CLL ManagementA discussion between Dr. Peter Anglin and Dr. Versha Banerji (June 2022)
Dr. Anglin and Dr. Banerji revisit the management of treatment naïve CLL in Canada. Dr. Banerji describes her approaches with novel agents focusing on initial screening for associated risk factors as well as prevention and management of common treatment-related adverse events. She covers concerns related to cardiovascular risks with BTKi, infusion reactions with obinutuzumab and tumour lysis syndrome with venetoclax.
Peter Anglin, MD, FRCPC, MBA, Hematologist/Oncologist, Physician Lead, Stronach Regional Cancer, Centre Newmarket, ON
Versha Banerji, MD, FRCPC, Clinician Scientist and Associate Professor, Faculty of Medicine, Departments of Internal Medicine, Biochemistry & Medical Genetics, Max Rady School of Medicine, Rady Faculty of Health Sciences, University of Manitoba, CLL clinic and research Co-Lead Hematologist, CancerCare Manitoba, Senior Scientist, CancerCare Manitoba Research Institute, Adjunct Professor, Department of Biology, University of Winnipeg
This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.